Inside Precision Medicine December 11, 2023
Malorye Branca

In a landmark moment for sickle cell disease treatment and CRISPR, two gene therapies were approved for the condition by the U.S. FDA. One of them,Vertex and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel [exa-cel]), is the first ever FDA approved CRISPR/Cas9 genome-edited cell therapy. Simultaneously, Bluebird Bio received the FDA OK for Lyfgenia, its gene therapy for sickle cell.

Bluebird said their treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy. This approval also marks Bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder.

Last month, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) was first to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article